Sign in Subscribe
5 min read Bulletin

Inside Look: A Former NHSA Official's Take on Pricing Medical Innovations

These perspectives provide unique insights into what may contribute to NHSA's decision criteria in pricing medical innovations and allocating healthcare resources.
Inside Look: A Former NHSA Official's Take on Pricing Medical Innovations

At the 7th Medical Innovation Ecosystem Conference (West Expo 2024) on April 9th, Xiong Xianjun, the former director of the Medical Services Management Department of the National Healthcare Security Administration, discussed market-based pricing for innovative drugs.

His speech offered a unique glimpse into the thinking of a past NHSA official, illuminating several crucial questions that the industry has been seeking more definitive answers to:

(1) How does the NHSA value and price medical innovations?

(2) What role does Pharmacoeconomics play in price negotiations?

(3) How does the NHSA manage to balance the needs of small patient groups (such as those needing orphan drugs) against those of the broader population (such as those needing drugs for major diseases) in its healthcare resource allocation?

His perspectives are valuable in understanding what may influence the NHSA’s decision-making processes and its guiding principles in navigating these complex issues.

Here's a summary of his speech, followed by my thoughts.

This post is for subscribers only


Published by:

Kelly Ke

You might also like...

Jul
10
5 Trillion-Yuan Equipment Renewal and China's National Quota System for Large Medical Equipment

5 Trillion-Yuan Equipment Renewal and China's National Quota System for Large Medical Equipment

In China, large medical equipment is managed through a planned allocation and permit system. Medical institutions must follow specific plans, meet clinical and functional requirements, and have the necessary technical infrastructure and qualified staff.
4 min read
Jul
03
NHSA Quietly Releases Implementation Guides for Establishing Medical Service Pricing Items

NHSA Quietly Releases Implementation Guides for Establishing Medical Service Pricing Items

Executive Summary In China, both public and private not-for-profit hospitals are required to adhere to the Medical Service Pricing Catalogs
5 min read
Jun
26
China Aims to Establish a High-Quality All-Inclusive Commercial Health Insurance System in Five Years

China Aims to Establish a High-Quality All-Inclusive Commercial Health Insurance System in Five Years

Executive Summary City Commercial Health Insurance ("Huiminbao") has been rapidly advancing, focusing on protecting the entire population against
4 min read
Jun
05
Accessing Innovative Orphan Therapies in China: Local Advancements

Accessing Innovative Orphan Therapies in China: Local Advancements

These local initiatives have developed unique early access programs and multi-level funding models for orphan therapies, addressing the core issue of covering high-cost rare disease drugs not included in the national catalog.
3 min read
Apr
24
China Local Pilots Expedite Access to Innovative Medicine

China Local Pilots Expedite Access to Innovative Medicine

These local experiments focus on speeding up clinical trials, broadening payment options, and incentivizing hospital listings to accelerate access to innovative drugs and medical devices.
4 min read